Cargando…

Inborn errors of immunity—recent advances in research on the pathogenesis

Primary immunodeficiency (PID) is a genetic disorder with a defect of one of the important components of our immune system. Classical PID has been recognized as a disorder with loss of function of the immune system. Recent studies have unveiled disorders with immune dysfunction with autoimmunity, au...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Motoi, Inoue, Kento, Okano, Tsubasa, Morio, Tomohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992775/
https://www.ncbi.nlm.nih.gov/pubmed/33766139
http://dx.doi.org/10.1186/s41232-021-00159-6
_version_ 1783669449114517504
author Yamashita, Motoi
Inoue, Kento
Okano, Tsubasa
Morio, Tomohiro
author_facet Yamashita, Motoi
Inoue, Kento
Okano, Tsubasa
Morio, Tomohiro
author_sort Yamashita, Motoi
collection PubMed
description Primary immunodeficiency (PID) is a genetic disorder with a defect of one of the important components of our immune system. Classical PID has been recognized as a disorder with loss of function of the immune system. Recent studies have unveiled disorders with immune dysfunction with autoimmunity, autoinflammation, allergy, or predisposition to malignancy. Some of them were caused by an augmented immune function or a defect in immune regulation. With this background, the term inborn errors of immunity (IEI) is now used to refer to PID in the International Union of Immunological Societies (IUIS) classification. More than 400 responsible genes have been identified in patients with IEI so far, and importantly, many of them identified lately were caused by a heterologous mutation. Moreover, the onset is not necessarily in childhood, and we started seeing more and more IEI patients diagnosed in adulthood in the clinical settings. Recent advances in genetic analysis, including whole-exome analysis, whole-genome analysis, and RNA-seq have contributed to the identification of the disease-causing gene mutation. We also started to find heterogeneity of phenotype even in the patients with the same mutation in the same family, leading us to wonder if modifier gene or epigenetic modification is involved in the pathogenesis. In contrast, we accumulated many cases suggesting genetic heterogeneity is associated with phenotypic homogeneity. It has thus become difficult to deduce a responsible gene only from the phenotype in a certain type of IEI. Current curative therapy for IEI includes hematopoietic cell transplantation and gene therapy. Other curative therapeutic modalities have been long waited and are to be introduced in the future. These include a small molecule that inhibits the gain-of-function of the molecule- and genome-editing technology. Research on IEI will surely lead to a better understanding of other immune-related disorders including rheumatic diseases and atopic disorders.
format Online
Article
Text
id pubmed-7992775
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79927752021-03-31 Inborn errors of immunity—recent advances in research on the pathogenesis Yamashita, Motoi Inoue, Kento Okano, Tsubasa Morio, Tomohiro Inflamm Regen Review Primary immunodeficiency (PID) is a genetic disorder with a defect of one of the important components of our immune system. Classical PID has been recognized as a disorder with loss of function of the immune system. Recent studies have unveiled disorders with immune dysfunction with autoimmunity, autoinflammation, allergy, or predisposition to malignancy. Some of them were caused by an augmented immune function or a defect in immune regulation. With this background, the term inborn errors of immunity (IEI) is now used to refer to PID in the International Union of Immunological Societies (IUIS) classification. More than 400 responsible genes have been identified in patients with IEI so far, and importantly, many of them identified lately were caused by a heterologous mutation. Moreover, the onset is not necessarily in childhood, and we started seeing more and more IEI patients diagnosed in adulthood in the clinical settings. Recent advances in genetic analysis, including whole-exome analysis, whole-genome analysis, and RNA-seq have contributed to the identification of the disease-causing gene mutation. We also started to find heterogeneity of phenotype even in the patients with the same mutation in the same family, leading us to wonder if modifier gene or epigenetic modification is involved in the pathogenesis. In contrast, we accumulated many cases suggesting genetic heterogeneity is associated with phenotypic homogeneity. It has thus become difficult to deduce a responsible gene only from the phenotype in a certain type of IEI. Current curative therapy for IEI includes hematopoietic cell transplantation and gene therapy. Other curative therapeutic modalities have been long waited and are to be introduced in the future. These include a small molecule that inhibits the gain-of-function of the molecule- and genome-editing technology. Research on IEI will surely lead to a better understanding of other immune-related disorders including rheumatic diseases and atopic disorders. BioMed Central 2021-03-25 /pmc/articles/PMC7992775/ /pubmed/33766139 http://dx.doi.org/10.1186/s41232-021-00159-6 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review
Yamashita, Motoi
Inoue, Kento
Okano, Tsubasa
Morio, Tomohiro
Inborn errors of immunity—recent advances in research on the pathogenesis
title Inborn errors of immunity—recent advances in research on the pathogenesis
title_full Inborn errors of immunity—recent advances in research on the pathogenesis
title_fullStr Inborn errors of immunity—recent advances in research on the pathogenesis
title_full_unstemmed Inborn errors of immunity—recent advances in research on the pathogenesis
title_short Inborn errors of immunity—recent advances in research on the pathogenesis
title_sort inborn errors of immunity—recent advances in research on the pathogenesis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992775/
https://www.ncbi.nlm.nih.gov/pubmed/33766139
http://dx.doi.org/10.1186/s41232-021-00159-6
work_keys_str_mv AT yamashitamotoi inbornerrorsofimmunityrecentadvancesinresearchonthepathogenesis
AT inouekento inbornerrorsofimmunityrecentadvancesinresearchonthepathogenesis
AT okanotsubasa inbornerrorsofimmunityrecentadvancesinresearchonthepathogenesis
AT moriotomohiro inbornerrorsofimmunityrecentadvancesinresearchonthepathogenesis